Procter & Gamble (PG), Teva (TEVA) Form Multi-Billion OTC Partnership
Tweet
Share
E-mailGet Alerts PG Hot Sheet
Join SI Premium – FREE
The Procter & Gamble Company (NYSE: PG) and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) have signed a master agreement to "create a partnership in consumer health care by bringing together both companies’ existing over-the-counter (OTC) medicines and complementary capabilities to accelerate growth."
Additionally, "The partnership will include a joint venture that combines the companies’ OTC businesses in all markets outside of North America. The markets included in the joint venture generated sales of more than $1 billion in 2010."
Closing is expected in late-2011.
Additionally, "The partnership will include a joint venture that combines the companies’ OTC businesses in all markets outside of North America. The markets included in the joint venture generated sales of more than $1 billion in 2010."
Closing is expected in late-2011.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Gray Media closes $750M note offering to refinance higher-rate debt
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
